Skip to main content
SpringerLink
Log in

Kolonkarzinom

Chirurgie und adjuvante Therapie stehen im Mittelpunkt der Behandlung

  • TOPIC 1 · kolonkarzinom
  • Published:
best practice onkologie Aims and scope

Bei der Behandlung von Patienten mit Kolonkarzinom steht zum einen die radikale Chirurgie und zum anderen die adjuvante Therapie im Fokus. Der Stellenwert der adjuvanten Therapie konnte in den letzten Jahren immer weiterentwickelt werden. Diese basiert heute weitgehend auf 5-Fluorouracil (5-FU).

Als Behandlungsstrategie hat sich entweder die Therapie mit 5-Fluorouracil/Folinsäure und Oxaliplatin oder alternativ eine Therapie mit Capecitabin als Standard etabliert. Weiterhin unklar ist der Stellenwert der adjuvanten Chemotherapie beim Kolonkarzinom im Stadium II. Der zusätzliche Einsatz von monoklonalen Antikörpern, wie Bevacizumab und Cetuximab in Kombination mit einer oxaliplatinhaltigen Chemotherapie werden derzeit geprüft.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Veldkamp R, Kuhry E, Hop WC et al. (2005) Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol 6: 477-484

    Article  PubMed  Google Scholar 

  2. Clinical Outcomes of Surgical Therapy Study Group (2004) A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 350: 2050-2059

  3. Guillou PJ, Quirke P, Thorpe H et al. (2005) Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 365: 1718-1726

    Article  PubMed  Google Scholar 

  4. Junginger T, Hossfeld DK, Sauer R et al. (1999) Adjuvante Therapie bei Kolon- und Rektumkarzinom. Dtsch Ärzteblatt 96: 536-538

    Google Scholar 

  5. Moertel C, Fleming TR, Macdonald JS et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon cancer. N Engl J Med 322: 352-358

    Article  PubMed  CAS  Google Scholar 

  6. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939-944

    Google Scholar 

  7. Haller DG, Catalano PJ, Macdonald JS et al. (2005) Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089. J Clin Oncol 23: 8671-8678

    Article  PubMed  Google Scholar 

  8. QUASAR Collaborative Group (2000) Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 355: 1588-1596

    Google Scholar 

  9. Andre T, Boni C, Mounedji-Boudiaf L, et al. (2003) Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351

    Article  Google Scholar 

  10. Andre T, Colin P, Louvet C et al. (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and II colon cancer: results of a randomized trial. J Clin Oncol 21: 2896-2903

    Article  PubMed  CAS  Google Scholar 

  11. Saini A, Norman AR, Cunningham D et al. (2003) Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 month of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88: 1859-1865

    Article  PubMed  CAS  Google Scholar 

  12. Kuebler JP, Wienand S, O'Connell J et al. (2007) Oxaliplatin combined with weekly bolus fluorouracil and leuvovorin as surgical adjuvant chemotherapy for stage II and II colon cancer: Results from NSABP C-07. J Clin Oncol 25: 2198-2204

    Article  PubMed  CAS  Google Scholar 

  13. Saltz LB, Niedzwiecki D, Hollis D et al. (2007) Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leukovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 25: 34566-3461

    Google Scholar 

  14. Van Cutsem et al. (2005) Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). PETACC 3. ASCO 2005, # 8

  15. Twelves C, Wong A, Nowacki MP et al. (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696-2704

    Article  PubMed  CAS  Google Scholar 

  16. International Multicentre Polled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356-1363

  17. Mamounas E, Wienand S, Wolmark N et al. (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes B versus Dukes C colon cancer: Results from four National Surgical Adjuvant Breast and Bowl Project Protocol studies (C- 01, C-02, C-03 and C-04). J Clin Oncol 17: 1349-1355

    PubMed  CAS  Google Scholar 

  18. Schrag D, Rifas-Shiman S, Salz L, et al. (2004) Adjuvant Chemotherapy use for Medicare beneficiaries with stage II Colon Cancer. J Clin Oncol 20: 3999-4005

    Article  Google Scholar 

  19. Gray RG, Barnwell J, Hills R et all. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J Clin Oncol (Meeting Abstracts) 22: 3501

  20. Sargent DJ, Goldberg RM, Jacobson SD et al. (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Hämatologie, Onkologie und Gastroenterologie, Kliniken Maria Hilf GmbH, Mönchengladbach

    U. Graeven

  2. Klinik für Viszeral-, Gefäss- und Transplantationschirurgie Zentrum für Chirurgie, Klinikum Köln-Merheim, Köln

    M. M. Heiss

  3. Klinik für Hämatologie, Onkologie und Gastroenterologie, Kliniken Maria Hilf GmbH, Viersener Str. 450, 41063, Mönchengladbach

    U. Graeven

  4. Klinik für Viszeral-, Gefäss- und Transplantationschirurgie, Klinikum Köln-Merheim, Ostmerheimer Str. 200, 51109, Köln

    M. M. Heiss

Authors
  1. U. Graeven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. M. Heiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to U. Graeven or M. M. Heiss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graeven, U., Heiss, M.M. Kolonkarzinom. best practice onkologie 3, 4–12 (2008). https://doi.org/10.1007/s11654-008-0033-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-008-0033-z

Search

Navigation